HILLSIDE, N.J., Dec. 20 /PRNewswire-FirstCall/ -- Integrated BioPharma, Inc. (Amex: INB) announced today that its AIPwLV(TM) proprietary technology platform was chosen again to be used for a specific product development, in this case for vaccine against malaria, as more particularly described in the December 15 announcement by Fraunhofer USA Center for Molecular Biotechnology ("FCMB") excerpted below:

     "Fraunhofer CMB Receives Gates Foundation Grant to Develop Innovative
     Malaria Vaccines

     The Fraunhofer USA Center for Molecular Biotechnology ("Fraunhofer CMB")
     announced today the receipt of a $3.5 million grant from the Bill &
     Melinda Gates Foundation to support the development of transmission-
     blocking vaccines against malaria. To achieve the goals of this project,
     Fraunhofer CMB will employ its proprietary platform technology to produce
     lifesaving vaccines in non-genetically modified plants.

     Despite a century of efforts, malaria remains a major cause of morbidity
     and mortality in tropical and subtropical regions throughout the world,
     causing more than 300 million acute cases and at least one million deaths
     annually. Malaria is the leading cause of death in young children in
     Africa, killing one child every 30 seconds.

     Vaccines could provide an effective means for the control and prevention
     of malaria. Previous research has shown that some human antibodies can
     reduce the transmission of malaria parasites from humans to mosquitoes.
     The project announced today will develop vaccine candidates designed to
     elicit these antibodies, thus preventing further spread of disease in
     endemic communities."

The AIPwLV(TM) Platform was developed for INB by FCMB over the last three years. It is a proprietary platform technology which, as applied to vaccines, uses quickly-grown, non-genetically modified plants as a medium for the rapid, economical production of vaccine antigens. Unlike vaccine technologies currently in use, the AIPwLV(TM) platform enables practically limitless scalability of production of target antigens for vaccines against such diseases as influenza, relatively quickly after identification of the active strain, thereby significantly increasing the availability of efficacious vaccines for large-scale inoculations. In addition to the malaria vaccine product development described in the FCMB announcement, the AIPwLV(TM) platform is currently being used for two other vaccine product developments, against influenza and trypanosomiasis.

"These vaccine product developments using our AIPwLV(TM) platform represent important first applications of this robust technology," said E. Gerald Kay, CEO of INB. "We expect the AIPwLV(TM) platform to alleviate or solve many of the problems affecting current vaccine technologies, and to be

used under licenses from us for the novel production of many vaccines and therapeutic protein-based products against other diseases," added Mr. Kay.

About Integrated BioPharma, Inc. (INB)

Integrated BioPharma presently serves the varied needs of the health care industry through its Nutraceutical business, which creates, develops, manufactures and markets health products worldwide; its Biotechnology business, which uses its patented plant-based technology to produce vaccines and therapeutic antibodies; and its Pharmaceutical business, which operates contract research and cGMP manufacturing facilities. Further information is available at www.iBioPharma.com.

Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

SOURCE Integrated BioPharma, Inc.